Tagged with VAT

Colombia Guillermo Gómez, managing director of the Andean region at Siemens Healthineers discusses Colombia’s evolution in terms of access to healthcare and investment in life-saving medical equipment, as well as the role Healthineers can play in reducing healthcare system costs and easing patient access. Those are exiting times for Siemens as…

Austria Clemens Schödl, general manager of Gilead Austria, discusses Gilead’s footprint and reputation in Austria as the leading global player in HIV treatment and what must be done to bring Austrian innovation into a new era to fully leverage Gilead’s life changing treatments. As general manager, could you introduce our international…

Colombia Eduardo Obraczka, managing director at Merck Colombia, shares his appreciation for the flexibility of the Colombian talent pool, while explaining Merck’s successful strategy that has led to the impressive growth of the organization in the country, and highlights how Merck is continuously fostering an innovative and dynamic environment. How does…

Colombia Adriana Forero, General Manager of GSK Colombia, speaks about their efforts to remain at the forefront of the healthcare industry, while keeping their focus on increasing access, innovation and focus on the patient in order to become a strategic partner for the Government and the Colombian healthcare system Ms. Forero,…

Canada Pamela C. Fralick, President of Innovative Medicines Canada (IMC), the innovative pharma association in Canada, looks back on her first half year in position, the challenges of navigating Canada’s complex and multifaceted health ecosystem, and her goal of bringing together all healthcare stakeholders in much-needed dialogue on how to improve…

Austria Prof. Johannes Khinast, CEO and scientific director, and Dr. Thomas Klein, CEO and business director of the Research Center Pharmaceutical Engineering, or RCPE, the world’s first pharmaceutical engineering company that combines simulation, formulation and processing for large international companies such as Pfizer, Bayer and Novartis, give an overview of the…

Colombia Oscar Fernando Otalora Gomez, Executive Director of HB Human Bioscience, discusses the importance of bringing innovation and technology to the Colombian market, while being committed to providing medication at a reasonable price to save lives. To begin with, could you introduce HB Human Bioscience to our international audience and give…

USA In an exclusive interview, Stephen Ubl, President and CEO of the Pharmaceutical Researchers and Manufacturers of America (PhRMA), the association representing the leading innovative biopharmaceutical companies in the USA, discusses the onset of a new “golden era” in medicine. He goes on to discuss pricing issues, engaging in a constructive…

Ukraine Julia Sidorova, country manager of Alvogen, a new international player to the Ukrainian market, provides insights into the targeted strategy that Alvogen employs throughout the world and how this is tailored to the specificities and needs of Ukraine’s health system, while she also highlights opportunities for potential partnerships in the…

Indonesia Evie Yulin, biopharma country director at Merck Indonesia, speaks towards the meaning of innovation in emerging countries and how the company engages in innovation beyond products. Since 2012, Merck has been implementing “Fit for 2018” – a transformation program aiming to drive the growth of the company globally. How has this…

Colombia Sandra Cifuentes, General Manager of Astellas Farma Colombia, one of the most recent entrants in the Colombian market, explains the strategic priorities for establishing a strong position in the country, where the prime focus is on bringing a collaborative approach that can unite the industry towards a more sustainable healthcare…

Austria Manuel Reiberg, president of the Forum of the Research-Based Pharmaceutical Industry in Austria (FOPI), which represents the 27 leading pharmaceutical innovators in Austria focused on pharmaceutical innovation, discusses the struggles facing drug innovation under the new reimbursement system, as well as the steps that must be taken to bolster the…